CN1682915A - 一种治疗***的药物及其制备方法 - Google Patents
一种治疗***的药物及其制备方法 Download PDFInfo
- Publication number
- CN1682915A CN1682915A CN 200510051424 CN200510051424A CN1682915A CN 1682915 A CN1682915 A CN 1682915A CN 200510051424 CN200510051424 CN 200510051424 CN 200510051424 A CN200510051424 A CN 200510051424A CN 1682915 A CN1682915 A CN 1682915A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- medicine
- rhizoma
- inflammatory disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 37
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 229940079593 drug Drugs 0.000 title claims description 9
- 241000218176 Corydalis Species 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 6
- 241000245240 Lonicera Species 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- -1 electuary Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 4
- 238000002481 ethanol extraction Methods 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 43
- 238000012360 testing method Methods 0.000 abstract description 32
- 208000024891 symptom Diseases 0.000 abstract description 20
- 230000001684 chronic effect Effects 0.000 abstract description 15
- 230000001154 acute effect Effects 0.000 abstract description 14
- 208000004998 Abdominal Pain Diseases 0.000 abstract description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 241000334154 Isatis tinctoria Species 0.000 abstract 1
- 240000000233 Melia azedarach Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 239000009910 sargent gloryvine Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 19
- 239000004615 ingredient Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 210000001015 abdomen Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000009826 distribution Methods 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 210000004291 uterus Anatomy 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 238000007689 inspection Methods 0.000 description 6
- 230000005906 menstruation Effects 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 229930013930 alkaloid Natural products 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 4
- 208000008035 Back Pain Diseases 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 150000003797 alkaloid derivatives Chemical class 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 229920001864 tannin Polymers 0.000 description 4
- 235000018553 tannin Nutrition 0.000 description 4
- 239000001648 tannin Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 206010060891 General symptom Diseases 0.000 description 3
- 229930183118 Tanshinone Natural products 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010000084 Abdominal pain lower Diseases 0.000 description 2
- 241000294743 Gamochaeta Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 208000019914 Mental Fatigue Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000002338 glycosides Chemical group 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 201000005630 leukorrhea Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000030208 low-grade fever Diseases 0.000 description 2
- 210000004705 lumbosacral region Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- GSZUGBAEBARHAW-UHFFFAOYSA-N sophoraflavone B Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C=2OC3=CC(O)=CC=C3C(=O)C=2)C=C1 GSZUGBAEBARHAW-UHFFFAOYSA-N 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 206010046901 vaginal discharge Diseases 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- KSDSYIXRWHRPMN-UHFFFAOYSA-N 4'-O-beta-D-Galactopyranoside-6''-p-Coumaroylprunin-4',5,7-Trihydroxyflavanone Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC(O)=C3C(=O)C2)C=C1 KSDSYIXRWHRPMN-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010011953 Decreased activity Diseases 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 208000016908 Female Genital disease Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- FURUXTVZLHCCNA-UHFFFAOYSA-N Liquiritigenin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-UHFFFAOYSA-N 0.000 description 1
- DEMKZLAVQYISIA-ONJCETCRSA-N Liquiritin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)c1ccc([C@@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1 DEMKZLAVQYISIA-ONJCETCRSA-N 0.000 description 1
- DEMKZLAVQYISIA-UHFFFAOYSA-N Liquirtin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(C2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-UHFFFAOYSA-N 0.000 description 1
- XYXONTIQGZKCNH-UYKXVWJOSA-N Lonicerin Natural products CO[C@@H]1O[C@@H](O)[C@H]([C@H]2C[C@H](O)[C@H](C)[C@@H]12)C(=O)OC XYXONTIQGZKCNH-UYKXVWJOSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- SHPPXMGVUDNKLV-UHFFFAOYSA-N Veronicastroside Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 SHPPXMGVUDNKLV-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 201000003988 chronic cervicitis Diseases 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 208000027692 gas pain Diseases 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- JBQATDIMBVLPRB-UHFFFAOYSA-N isoliquiritigenin Natural products OC1=CC(O)=CC=C1C1OC2=CC(O)=CC=C2C(=O)C1 JBQATDIMBVLPRB-UHFFFAOYSA-N 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- FURUXTVZLHCCNA-AWEZNQCLSA-N liquiritigenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC=C2C(=O)C1 FURUXTVZLHCCNA-AWEZNQCLSA-N 0.000 description 1
- DEMKZLAVQYISIA-ZRWXNEIDSA-N liquiritin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C([C@H]2OC3=CC(O)=CC=C3C(=O)C2)C=C1 DEMKZLAVQYISIA-ZRWXNEIDSA-N 0.000 description 1
- SHPPXMGVUDNKLV-KMFFXDMSSA-N luteolin 7-O-neohesperidoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=C(O)C(O)=CC=3)OC2=C1 SHPPXMGVUDNKLV-KMFFXDMSSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 208000010669 pelvic lump Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 例数 | 30岁以下N(%) | 30~50N(%) | 50~N(%) |
试验组对照组 | 15050 | 30(20.2)11(22.0) | 87(58.0)27(54.0) | 33(22.0)12(24.0) |
组别 | 例数 | 工人N(%) | 干部N(%) | 农民N(%) | 其它N(%) |
试验组对照组 | 15050 | 50(33.3)17(34) | 44(29.3)14(28.0) | 30(20)11(22) | 26(17.3)8(16.0) |
组别 | 例数 | 急性***N(%) | 慢性***N(%) |
试验组对照组 | 15050 | 54(36)17(34) | 96(64)33(66) |
组别 | 例数 | 痊愈N(%) | 显效N(%) | 有效N(%) | 无效N(%) | 总有效N(%) |
试验组对照组 | 15050 | 82(55)17(34) | 48(32)15(30) | 8(5)7(14.7) | 12(8)11(22) | 138(92)39(78.7) |
组别 | 例数 | 痊愈N(%) | 显效N(%) | 有效N(%) | 无效N(%) | 总有效N(%) |
急性***慢性*** | 5496 | 20(37)41(42.7) | 17(31)30(31.2) | 13(24)17(17.8) | 4(7.4)8(8.3) | 50(92)88(91.7) |
组别 | 例数 | 痊愈N(%) | 显效N(%) | 有效N(%) | 无效N(%) | 总有效N(%) |
<3030~35~ | 308535 | 12(40.0)33(38.8)14(40) | 7(23.3)20(23.5)9(25.7) | 8(26.7)19(22.3)8(22.9) | 3(10.0)13(15.4)4(11.4) | 27(90.0)72(84.6)31(88.6) |
职业 | 例数 | 痊愈N(%) | 显效N(%) | 有效N(%) | 无效N(%) | 总有效N(%) |
工人干部农民其它 | 50443026 | 20(40.0)20(45.5)10(33.3)12(46.0) | 12(24.0)11(25.0)11(36.7)8(30.8) | 12(24.0)10(22.7)6(20.0)4(15.4) | 6(12.0)3(6.8)3(10.0)2(7.7) | 42(88.0)41(93.2)27(90.0)24(92.3) |
证型 | 例数 | 痊愈N(%) | 显效N(%) | 有效N(%) | 无效N(%) | 总有效N(%) |
瘀毒内结证气滞血瘀证 | 7179 | 32(45.1)25(31.6) | 18(25.4)29(36.7) | 15(21.1)17(21.5) | 6(8.5)8(10.0) | 65(91.5)71(89.8) |
症状 | 试验组 | 对照组 | P值 | ||||
治疗前 | 有效例 | 有效率(%) | 治疗前 | 有效例 | 有效率(%) | ||
***白带异常下腹疼痛腰酸头晕、气短心胸烦闷面色少华口干食欲不振尿黄、便秘高热盆腔淤血 | 15015015015057556951150150147150 | 13813513812752486036146130125130 | 929092859287877098888887 | 505050502220201950505350 | 404041421816171545403738 | 808082858280857990806977 | <0.05<0.05<0.05<0.05<0.05<0.05>0.05<0.05<0.05<0.05<0.05<0.05 |
疗程 | 例数 | 治愈(%) | 好转(%) | 无效(%) |
1疗程1-2疗程 | 150150 | (105)70(130)87 | (20)13(8)5 | (25)17(12)8 |
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100514241A CN100388931C (zh) | 2005-03-04 | 2005-03-04 | 一种治疗***的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100514241A CN100388931C (zh) | 2005-03-04 | 2005-03-04 | 一种治疗***的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1682915A true CN1682915A (zh) | 2005-10-19 |
CN100388931C CN100388931C (zh) | 2008-05-21 |
Family
ID=35262534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100514241A Expired - Fee Related CN100388931C (zh) | 2005-03-04 | 2005-03-04 | 一种治疗***的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100388931C (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100453099C (zh) * | 2006-04-07 | 2009-01-21 | 重庆希尔安药业有限公司 | 一种治疗妇女***的制剂及其制备方法 |
CN101301414B (zh) * | 2008-06-06 | 2010-12-15 | 张宗保 | 一种治疗***的中药及制备方法 |
US8795742B2 (en) | 2006-01-20 | 2014-08-05 | Livzon Pharmaceutical Group Inc. | Chinese traditional medicine composition for treatment of avian influenza, method for preparation and application thereof |
-
2005
- 2005-03-04 CN CNB2005100514241A patent/CN100388931C/zh not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8795742B2 (en) | 2006-01-20 | 2014-08-05 | Livzon Pharmaceutical Group Inc. | Chinese traditional medicine composition for treatment of avian influenza, method for preparation and application thereof |
US9265805B2 (en) | 2006-01-20 | 2016-02-23 | Livzon Pharmaceutical Group Inc. | Chinese traditional medicine composition for treatment of avian influenza, method for preparation and application thereof |
CN100453099C (zh) * | 2006-04-07 | 2009-01-21 | 重庆希尔安药业有限公司 | 一种治疗妇女***的制剂及其制备方法 |
CN101301414B (zh) * | 2008-06-06 | 2010-12-15 | 张宗保 | 一种治疗***的中药及制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100388931C (zh) | 2008-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102727779B (zh) | 一种治疗***的药物组合物及其制备方法 | |
CN101537159B (zh) | 一种中药组合物及其制备方法和应用 | |
CN104784511A (zh) | 一种治疗冠心病的药物 | |
CN100388931C (zh) | 一种治疗***的药物及其制备方法 | |
CN103055284A (zh) | 治疗溃疡性结肠炎的中药及其制备方法 | |
CN103356932B (zh) | 一种治疗外阴鳞状上皮细胞增生的药物组合物 | |
CN100335087C (zh) | 一种治疗妇科***部疾病的中药制剂 | |
CN1843421A (zh) | 一种治疗风湿疾病的药物 | |
CN104524247A (zh) | 一种治疗偏头痛的药物组合物及其用途 | |
CN101596270B (zh) | 一种用于治疗慢性咽炎的药物及其制备方法 | |
CN105250954B (zh) | 一种治疗肠易激综合征的中药及其制备方法 | |
CN103285284A (zh) | 一种治疗老年性***炎的药物组合物 | |
CN1253196C (zh) | 一种治疗结肠炎的药物 | |
CN103142897B (zh) | 一种贲门失弛缓症术后用药 | |
CN105435210A (zh) | 一种治疗寒湿痹阻型腰椎间盘突出症的中医定向透药治疗液及其制备方法 | |
CN105106674A (zh) | 一种治疗老年性皮肤瘙痒症的中药组合物及其制备方法 | |
CN105343313A (zh) | 一种治疗老年性皮肤瘙痒症的中药组合物及其制备方法 | |
CN104258275A (zh) | 一种用于治疗瘀血内结型良性卵巢肿瘤的中药组合物 | |
CN103142898B (zh) | 一种贲门失弛缓症术后用药的制备方法 | |
CN103656199B (zh) | 一种治疗肾阴不足证型咳嗽的中药 | |
CN101224264A (zh) | 治疗创伤水肿的中药组合物及其制备方法 | |
CN102698130A (zh) | 一种治疗手术后肠粘连中药浸膏 | |
CN102961704A (zh) | 一种用于治疗肝癌的药物组合物及其分散片制备方法 | |
CN102824471B (zh) | 治疗腰椎间盘突出、坐骨神经痛和腿痛的中药 | |
CN1299748C (zh) | 一种减肥调理补气袋 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: YANGLING DONGKE MAIDISEN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHAO DONGKE Effective date: 20100617 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 712100 NO.8, XINQIAO ROAD, YANGLING DEMONSTRATION ZONE, SHANXI PROVINCE TO:710043 4/F, DONGXINGKEJI BUILDING, XINCHENG SCI-TECH INDUSTRY PARK, NO.1, XINKE ROAD, XI AN CITY, SHANXI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20100617 Address after: 710043 4 floor, Dongxing science and technology building, Xincheng science and Technology Industrial Park, No. 1, Xinke Road, Shaanxi, Xi'an Patentee after: Dongke Maidisen Pharmaceutical Co., Ltd., Yangling Address before: 712100 No. 8 Xinqiao Road, Yangling demonstration area, Shaanxi Patentee before: Zhao Dongke |
|
C35 | Partial or whole invalidation of patent or utility model | ||
IW01 | Full invalidation of patent right |
Decision date of declaring invalidation: 20090831 Decision number of declaring invalidation: 13754 Granted publication date: 20080521 |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080521 Termination date: 20120304 |